We are grateful for the critical comments of Thiele et al. because they give us the opportunity to underline the difficulties in applying the current World Health Organization (WHO) classification of thrombocytic myeloproliferative neoplasms and to eliminate potential misunderstandings.
References
- Buhr T, Hebeda K, Kaloutsi V, Porwit A, Van Der Walt J, Kreipe HH. European Bone Marrow Working Group trial on reproducibility of WHO criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica. 2011. Google Scholar
- Wilkins BS, Erber WN, Bareford D, Buck G, Wheatley K, East CL. Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood. 2008; 111(1):60-70. PubMedhttps://doi.org/10.1182/blood-2007-05-091850Google Scholar
- Brousseau M, Parot-Schinkel E, Moles MP, Boyer F, Hunault M, Rousselet MC. Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis. Histopathology. 2010; 56(6):758-67. PubMedhttps://doi.org/10.1111/j.1365-2559.2010.03545.xGoogle Scholar
- Spivak JL, Silver RT. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood. 2008; 112(2):231-9. PubMedhttps://doi.org/10.1182/blood-2007-12-128454Google Scholar
- Thiele J, Kvasnicka HM, Müllauer L, Buxhofer-Autsch V, Gisslinger B, Gisslinger H. Essential thromobcythemia versus early primary myelofibrosis – a multicenter study to validate WHO classification. Blood. 2011; 117(21):5710-8. PubMedhttps://doi.org/10.1182/blood-2010-07-293761Google Scholar
- Kreipe HH, Beham-Schmid C, Dirnhofer S, Hebeda K, Kaloutsi V, Porwit A, Van Der Walt J. Blood. 2011. Google Scholar
- Hussein K, Bock O, Theophile K, von Neuhoff N, Buhr T, Schlué J. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis. Exp Hematol. 2009; 37(10):e7-93. PubMedhttps://doi.org/10.1016/j.exphem.2009.07.005Google Scholar
- Burkhardt R, Bartl R, Jäger K, Frisch B, Kettner G, Mahl G, Sund M. Working classification of chronic myeloproliferative disorders based on histological, haematological, and clinical findings. J Clin Pathol. 1986; 39(3):237-52. PubMedhttps://doi.org/10.1136/jcp.39.3.237Google Scholar
- Georgii A, Buhr T, Buesche G, Kreft A, Choritz H. Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies. Leuk Lymphoma. 1996; 22(Suppl 1):15-29. PubMedhttps://doi.org/10.3109/10428199609074357Google Scholar
- Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951; 6(4):372-5. PubMedGoogle Scholar
- Spivak JL, Silver RT. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis: an alternative proposal. Blood. 2008; 112(2):231-9. PubMedhttps://doi.org/10.1182/blood-2007-12-128454Google Scholar
- Harrison CN, Bareford D, Butt N, Campbell P, Conneally E, Drummond M. Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol. 2010; 149(3):352-75. PubMedhttps://doi.org/10.1111/j.1365-2141.2010.08122.xGoogle Scholar
- Cervantes F. Management of essential thrombocythemia. Hematology Am Soc Hematol Educ Program. 2011; 2011:215-21. PubMedhttps://doi.org/10.1182/asheducation-2011.1.215Google Scholar